Placeholder Banner

BIO Submits Comments on Medicare CY 2020 Part D Draft Call Letter

March 20, 2019

BIO submitted comments on the Centers for Medicare and Medicaid Service’s Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter.

BIO supports CMS’s commitment to improving the quality and delivery of care in the MA and Part D programs. It’s critically important to ensure these programs advance patient access to timely and appropriate treatment, particularly for prescription drugs and vaccines. BIO provided comments on how to update and clarify the policies and provide greater access to patients while mitigating OOP costs.

Download Full Comments Below
FINAL BIO CY 2020 Draft Call Letter Comments 1 March 2019
See the full comment letter here:
Discover More
In a recent letter, BIO’s Jim Greenwood commended Representative Steil (R-WI) for introducing the “Helping Startups Continue to Grow Act,” which extends the exemption afforded to Emerging Growth Companies under the JOBS Act from certain executive…
In a letter to Chairman Grassley (R-IA) and Ranking Member Wyden (D-OR), the leaders of the Senate Finance Committee, state biotech associations warn that the Committee’s proposed redesign of Medicare Part D puts new, innovative treatments for…
The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance titled Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and…